PMI-150 (intranasal ketamine)

DRUG2 trials

Sponsors

Hospira, now a wholly owned subsidiary of Pfizer

Conditions

CancerPainPain, Postoperative

Phase 3

Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients

TerminatedNCT00492388

Hospira, now a wholly owned subsidiary of PfizerCancer, Pain

Start: 2007-06-30End: 2011-08-31Updated: 2012-01-11

Safety and Efficacy of Repeated Doses of PMI-150 (Intranasal Ketamine) in Acute Post-operative Pain Following Orthopedic Surgery

CompletedNCT00709436

Hospira, now a wholly owned subsidiary of PfizerPain, Postoperative

Start: 2008-06-30End: 2011-08-31Updated: 2012-01-11